8-K current report · filed Oct 28, 2026

GLAUKOS Corp (GKOS) 8-K Current Report: October 28, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2GKOS overview

Short answer

GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for quarter ended September 30, 2026 announced.

GLAUKOS Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Press release issued October 28, 2026, with results in Exhibit 99.1
  • Investor focus: quarterly performance details, guidance and outlook contained in the exhibit

Item 7.01 · Regulation FD Disclosure

  • Quarterly Summary covers Glaukos’ third quarter ended September 30, 2026
  • Supplemental business and financial information available in Exhibit 99.2
  • Investor relevance: additional quarterly operating detail beyond the core 8-K disclosure

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $211.0M, up 58%, led by Corneal Health growth of 154% and U.S. Glaucoma growth of 47%
  • Gross margin expanded to 85.2% from 78.4%, supporting GAAP operating income of $0.8M versus a $16.4M loss
  • GAAP net income $2.0M, or $0.03 diluted EPS, versus a $16.2M loss, though non-GAAP results exclude $26.5M of adjustments
  • Cash, investments and restricted cash rose to $339.8M, with no debt, strengthening funding capacity for growth and development
  • 2026 sales guidance raised to $775M-$785M, while preliminary 2027 guidance of $1B signals continued iDose TR and Epioxa momentum

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $211.0M, up 58%, with iDose TR sales approximately $76M and Epioxa sales approximately $53M
  • Non-GAAP operating income $27.3M versus $9.3M loss, signaling operating leverage despite higher commercial and R&D investment
  • FY2026 revenue guidance raised to $775-$785M from $680-$700M, reflecting accelerating iDose TR and Epioxa commercialization
  • Preliminary FY2027 revenue guidance of $1B, establishing a high-growth target dependent on continued product adoption and reimbursement execution
  • Cash, investments and restricted cash $339.8M, up $50.5M sequentially, strengthening funding for launches and pipeline development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GLAUKOS Corp 8-K filings

Get the next GKOS 8-K as it lands

Follow GKOS for push alerts, or ask the research agent what this filing means.